Status:
COMPLETED
Ghrelin and Diastolic Heart Function
Lead Sponsor:
University of Campania Luigi Vanvitelli
Conditions:
Diabetes Mellitus, Type 2
Obesity, Abdominal
Eligibility:
All Genders
18-75 years
Brief Summary
In type 2 diabetes mellitus (T2DM) and obese patients the adipose tissue could over-express cytokines, sirtuin-1 (SIRT1), and microRNAs (miRs) implied in the regulation of left ventricle (LV) diastoli...
Eligibility Criteria
Inclusion
- Clinical diagnosis of T2DM obese patients;
- T2DM obese patients under anti-diabetic full medical therapy and glycemic control.
Exclusion
- clinical diagnosis of type 1 diabetes;
- T2DM patients in poor glycemic control (HbA1c values of \>7%);
- chronic neurological disorders;
- heart failure and coronary heart disease or depression of left ventricular ejection fraction (LVEF \<55%);
- severe anemia;
- thyroid dysfunction;
- kidney failure;
- uncontrolled blood pressure (blood pressure \> 140/90 mmHg on two occasions 2 weeks apart);
- inflammatory chronic disease;
- neoplastic disease.
Key Trial Info
Start Date :
January 1 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2022
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05988346
Start Date
January 1 2016
End Date
March 1 2022
Last Update
August 24 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Celestino Sardu
Naples, Italy, 80138